AQXP Aquinox Pharmaceuticals Inc

Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 17th Annual Needham Healthcare Conference in New York on Wednesday, March 28th 2018.

Aquinox Presentation Details

Date: Wednesday, March 28th 2018 Time: 2:00 pm Eastern Time / 11:00 am Pacific Time                                   Location: New York, NY – Westin New York Grand Central

A live audio webcast and archive of the event will be available at:

http://wsw.com/webcast/needham86/aqxp/

To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.

About Aquinox Pharmaceuticals, Inc.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.

Investor Contact Info:

Brendan PayneAssociate Director, Investor Relations Aquinox Pharmaceuticals, Inc.604.901.3019ir@aqxpharma.com

Gitanjali OgawaVice President The Trout Group
646-378-2949
Gogawa@troutgroup.com